Traditional androgen ablation approaches to advanced prostate cancer: new insights.

摘要: Introduction Androgen deprivation therapy (ADT) is a mature for the treatment of advanced prostate cancer, and yet despite many years use, there still much about its side effects, efficacy, outcomes which urology community does not have answers. Materials methods A literature search was performed to review ADT use in modern era, specifically examining adjuvant after primary therapy, continuous versus intermittent ADT, disadvantages luteinizing hormone releasing (LHRH) agonists newer LHRH antagonists, controversies combined androgen blockade. Results has little role as North American populations. Evidence neoadjuvant/adjuvant with radical prostatectomy less compelling than that radiation therapy. Data supporting blockade over agonist alone are mixed. Newer antagonists faster onset reduction serum testosterone demonstrate other effects on follicle stimulating (FSH) may impact cancer outcomes. Conclusions remains mainstay our knowledge effectiveness improved time. There scenarios where enough information available study ongoing.